WillItSurvive
No grouping · United States

20/20 Biolabs, Inc.

Tiny AI blood test maker for early cancer screening, sold mostly through fire department contracts.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from January 13, 2027 · Every call on the record Checkpoint: Nasdaq minimum bid price compliance deadline
The call

A small AI cancer-test company with falling sales, a shrinking cash pile, and Nasdaq delisting risk sits next to far larger, better-funded screening rivals.

20/20 Biolabs makes blood tests that use AI to spot multiple cancer types early. The company is running out of money (under four million dollars in the bank, spending two million per quarter) while much larger competitors like GRAIL and Exact Sciences are already winning patients and doctor relationships with similar tests backed by billions of dollars. What could change everything: the company either needs to raise new cash soon, strike a deal with another company, or convince a major investor that its artificial intelligence approach is truly better than what GRAIL and Guardant are already doing with their own AI and bigger databases.

Why
01
AI pressure: Exact Sciences' Cancerguard and Guardant Health's Shield AI-driven screening models. Rivals train cancer-detection AI on far larger patient datasets, turning 20/20's own AI pitch into their weak point. Could AI do the core job? Yes, likely.
02
Bigger players: GRAIL, Inc. (Galleri). GRAIL's Galleri already dominates multi-cancer early detection with a huge NHS trial and payer relationships 20/20 lacks. Could a giant copy it? Yes, easily.
03
What protects it. Niche occupational screening deals with fire departments and government agencies that bigger players have not targeted.
What would change this call
Whether AIDX regains Nasdaq bid-price compliance before Jan 13, 2027. Shows if 20/20 Biolabs avoids delisting or faces forced reverse split.
Whether Streeterville Series E standstill converts to common stock around mid-Nov 2026. Shows whether dilution and share price collapse follow before fresh capital arrives.
Whether the Taipei/Tokyo/Seoul tour yields an announced M&A, licensing, or JV deal within 6 months. Shows if 20/20 Biolabs secures a strategic partner or capital lifeline.
Key numbers
  • Cash on hand $4.22M (2026-03-31)
  • Q1 2026 revenue $353K, down from $554K a year earlier (2026-03-31)
  • Q1 2026 net loss $2.17M (2026-03-31)
Named risks
  • Nasdaq delisting if bid price compliance not regained by January 13, 2027. Severity: high
  • Cash of $4.22M against quarterly burn over $2M leaves roughly two quarters of runway. Severity: high
  • Series E preferred standstill expires around mid-November 2026, opening path to dilutive conversions. Severity: medium
  • Q1 2026 revenue fell year over year to $353,375 from $553,820, reversing prior growth trend. Severity: medium
  • Vastly better funded MCED rivals (GRAIL, Exact Sciences, Guardant) can replicate its AI biomarker approach with more data. Severity: high
Rivals, as read in July 2026
RivalDirectionEvidence
GRAILlosing toGalleri leads MCED field; NHS-Galleri trial data reported at ASCO on Jun 4, 2026 showed 4x cancer detection rate
Exact Scienceslosing toLaunched Cancerguard multi-biomarker MCED test in US Sep 2025, directly competing with OneTest
Guardant Healthlosing toRoughly $19B market cap, FDA-approved Shield test since mid-2024, expanding toward MCED
Freenomelosing toCompany-reported raise of over $250M in late 2024 for its Sandpiper MCED study, dwarfing 20/20's capital base
Questions people ask
Is 20/20 Biolabs profitable in 2026?
No. 20/20 Biolabs posted a net loss of $2,174,836 in Q1 2026, while revenue fell to $353,375 from $553,820 a year earlier as of March 31, 2026, showing both a widening loss and shrinking sales.
Could AI replace what 20/20 Biolabs does?
20/20 Biolabs' own OneTest platform is AI powered, using machine learning over protein biomarkers, which is exactly the layer better funded rivals like GRAIL and Exact Sciences, whose Cancerguard test launched in September 2025, can replicate with more data.
Is 20/20 Biolabs at risk of being delisted from Nasdaq?
Yes. Nasdaq issued a non-compliance notice on July 17, 2026 for the Bid Price Rule after AIDX traded under $1 for 30 straight business days; the company has until January 13, 2027 to regain compliance or face delisting.
Who is 20/20 Biolabs' biggest competitor?
GRAIL's Galleri test dominates multi-cancer early detection, Exact Sciences launched its competing Cancerguard test in September 2025, and Guardant Health, with a roughly $19B market cap, has FDA approval for its Shield test as of mid-2024 and is expanding into MCED.
Who owns 20/20 Biolabs and is it public?
20/20 Biolabs has traded publicly on Nasdaq as AIDX since February 19, 2026 via direct listing. Streeterville Capital holds Series E Convertible Preferred Stock under a standstill agreement effective July 16, 2026 limiting near-term conversion to common shares.
Does 20/20 Biolabs have enough cash to survive the next year?
Cash was $4.14M at year end 2025, rose to $5.8M after a February 2026 preferred raise, then fell to $4.22M by the Q1 10-Q filing date, against quarterly losses exceeding $2M, implying roughly two quarters of runway without new capital.
Timeline
  • 2026-07-27Management tours Taipei, Tokyo, Seoul for East Asia roll-up strategy talks
  • 2026-07-2320/20 Biolabs announces 120-day standstill with Streeterville Capital on Series E preferred
  • 2026-07-17Nasdaq issues non-compliance notice for Bid Price Rule violation
  • 2026-06-04GRAIL reports full NHS-Galleri trial results at ASCO 2026
  • 2026-05-2020/20 Biolabs reports Q1 2026 financial results
  • 2026-03-3120/20 Biolabs reports FY2025 revenue of $2.05M, up 17% year over year
  • 2026-02-25OneTest for Longevity launches using IBM watsonx.ai
  • 2026-02-1920/20 Biolabs begins trading on Nasdaq as AIDX and closes $5M private placement
  • 2025-09Exact Sciences launches Cancerguard, a direct MCED competitor
  • 2025-03-19Company renamed 20/20 Biolabs, Inc.
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources